BMC Cancer (Jan 2022)

Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study

  • Yukinori Ozaki,
  • Yosuke Aoyama,
  • Jun Masuda,
  • Lina Inagaki,
  • Saori Kawai,
  • Tomoko Shibayama,
  • Tetsuyo Maeda,
  • Mami Kurata,
  • Kazuyo Yoshida,
  • Sumito Saeki,
  • Mari Hosonaga,
  • Ippei Fukada,
  • Fumikata Hara,
  • Takayuki Kobayashi,
  • Kokoro Kobayashi,
  • Satoshi Miyake,
  • Toshimi Takano,
  • Takayuki Ueno,
  • Shinji Ohno

DOI
https://doi.org/10.1186/s12885-021-09128-1
Journal volume & issue
Vol. 22, no. 1
pp. 1 – 7

Abstract

Read online

Abstract Background Trastuzumab and fulvestrant combination therapy is one of the treatment options for patients with hormone receptor- and human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer; however, there are limited studies evaluating the efficacy of this combination therapy. Methods We retrospectively reviewed the data of women with hormone receptor- and HER2-positive metastatic breast cancer who received trastuzumab and fulvestrant combination therapy between August 1997 and August 2020 at the Cancer Institute Hospital. The primary endpoint of this study was progression-free survival, and the secondary endpoints were response rate, overall survival and safety. Results We reviewed the data of 1612 patients with recurrent or metastatic breast cancer, of which 118 patients were diagnosed with hormone receptor- and HER2-positive breast cancer. Of these, 28 patients who received trastuzumab and fulvestrant combination therapy were eligible for this study. The median treatment line for advanced breast cancer was 6 (range, 1–14), the median progression-free survival was 6.4 months (95% confidence interval [CI], 3.46–8.17), and the median overall survival was 35.3 months (95% CI, 20.0–46.7). Of the 28 patients, partial response was observed in 1 (4%), stable disease in 17 (61%), and progressive disease in 10 (36%) patients. The disease control rate was 64%. Adverse events of grade ≥ 3 were not observed. Conclusions Trastuzumab and fulvestrant combination therapy showed moderate clinical efficacy and no severe toxicity after standard anti-HER2 treatment, which is a reasonable treatment option for patients with hormone receptor- and HER2-positive metastatic breast cancer. These data contribute to understanding the efficacy of trastuzumab and fulvestrant combination therapy as control data for further development of anti-HER2 agents plus hormone therapy.

Keywords